ABT-737 [Ligand Id: 8320] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL376408 (Abt 737, Abt-737, ABT-737) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| BCL2 apoptosis regulator/Apoptosis regulator Bcl-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4860] [GtoPdb: 2844] [UniProtKB: P10415] | ||||||||
| ChEMBL | Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance analysis | B | 9.22 | pKd | 0.6 | nM | Kd | ACS Med Chem Lett (2013) 4: 186-190 [PMID:24900652] |
| ChEMBL | Inhibition of Bcl2 (unknown origin) | B | 6.55 | pKi | 283 | nM | Ki | Eur J Med Chem (2019) 177: 63-75 [PMID:31129454] |
| ChEMBL | Binding affinity to BCL2 (unknown origin) by fluorescence polarization assay | B | 6.92 | pKi | 120 | nM | Ki | Medchemcomm (2016) 7: 778-787 |
| ChEMBL | Binding affinity to BCl2 | B | 8.1 | pKi | 8 | nM | Ki | J Med Chem (2010) 53: 6779-6810 [PMID:20925433] |
| GtoPdb | - | - | 9 | pKi | <1 | nM | Ki | J Med Chem (2007) 50: 641-62 [PMID:17256834] |
| ChEMBL | Binding affinity to Bcl-2 by competitive fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | Bioorg Med Chem Lett (2012) 22: 39-44 [PMID:22172701] |
| ChEMBL | Binding affinity to Bcl-2 | B | 9 | pKi | <1 | nM | Ki | Eur J Med Chem (2012) 51: 286-293 [PMID:22425031] |
| ChEMBL | Binding affinity to Bcl2 | B | 9 | pKi | <1 | nM | Ki | Eur J Med Chem (2012) 57: 112-125 [PMID:23047228] |
| ChEMBL | Displacement of Bax-derived peptide from Bcl2 by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Binding affinity to Bcl-2 (unknown origin) fluorescence polarization assay | B | 9 | pKi | 1 | nM | Ki | Bioorg Med Chem (2013) 21: 11-20 [PMID:23206987] |
| ChEMBL | Binding affinity to Bcl-2 (unknown origin) | B | 9 | pKi | <=1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| ChEMBL | Inhibition of 5-FAM-Bid peptide binding to Bcl-2 (unknown origin) by fluorescence polarization assay | B | 9 | pKi | 1 | nM | Ki | Bioorg Med Chem Lett (2016) 26: 5207-5211 [PMID:27712939] |
| ChEMBL | Inhibition of Bcl-2 (unknown origin) | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2017) 60: 821-838 [PMID:27749061] |
| ChEMBL | Inhibition of Bcl2 (unknown origin) | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2018) 61: 2636-2651 [PMID:28926247] |
| ChEMBL | Inhibition of BCL-2 (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay | B | 9 | pKi | <=1 | nM | Ki | Eur J Med Chem (2019) 167: 76-95 [PMID:30769242] |
| ChEMBL | Binding affinity to Bcl-2 | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2012) 55: 10735-10741 [PMID:23167494] |
| ChEMBL | Binding affinity to BCL2 | B | 9 | pKi | <=1 | nM | Ki | Proc Natl Acad Sci U S A (2007) 104: 19512-19517 [PMID:18040043] |
| ChEMBL | Displacement of fluorescein labeled Bax peptide from Bcl2 by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2008) 51: 6902-6915 [PMID:18841882] |
| ChEMBL | Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay | B | 9.22 | pKi | <0.6 | nM | Ki | J Med Chem (2012) 55: 4664-4682 [PMID:22448988] |
| ChEMBL | Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis | B | 7.7 | pIC50 | 20 | nM | IC50 | ACS Med Chem Lett (2013) 4: 186-190 [PMID:24900652] |
| ChEMBL | Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay | B | 8.15 | pIC50 | 7 | nM | IC50 | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay | B | 8.21 | pIC50 | 6.1 | nM | IC50 | J Med Chem (2011) 54: 1914-1926 [PMID:21366295] |
| ChEMBL | Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay | B | 8.7 | pIC50 | 2 | nM | IC50 | J Med Chem (2012) 55: 4664-4682 [PMID:22448988] |
| ChEMBL | Inhibition of Bcl2 | B | 9 | pIC50 | <1 | nM | IC50 | Bioorg Med Chem (2012) 20: 4194-4200 [PMID:22739087] |
| ChEMBL | Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS | F | 6.07 | pEC50 | 850 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS | F | 6.66 | pEC50 | 220 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 10% HS | F | 6.82 | pEC50 | 150 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS | F | 6.89 | pEC50 | 130 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS | F | 7.3 | pEC50 | 50 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of GST-tagged recombinant Bcl2 interaction with biotinylated Bim peptide by ELISA based competitive binding assay | B | 7.52 | pEC50 | <30 | nM | EC50 | Eur J Med Chem (2012) 57: 112-125 [PMID:23047228] |
| ChEMBL | Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 3% FBS | F | 7.85 | pEC50 | 14 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS | F | 8.08 | pEC50 | 8.3 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin | F | 8.1 | pEC50 | 8 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| BCL2 apoptosis regulator/Apoptosis regulator Bcl-2 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3309111] [GtoPdb: 2844] [UniProtKB: P10417] | ||||||||
| ChEMBL | Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The inhibition constant (Ki) is the dissociation constant of an enzyme-inhibitor complex or a protein/small molecule complex, wherein the small molecule is inhibiting binding of one protein to another protein or peptide. Where the Ki for a compound is represented as > (greater than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for Bcl-XL) is greater than the limits of detection of the assay used. Where the binding selectivity ratio for a compound is represented as > (greater than) a certain numerical value, it is intended to mean that the selectivity of a particular compound for Bcl-2 over Bcl-XL is at least as great as the number indicated. Where the Ki for a compound is represented as < (less than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for Bcl-2) is lower than the limit of detection of the assay used. Inhibition constants were determined using Wang's equation (Wang Z-X). | B | 10.06 | pKi | 0.09 | nM | Ki | US-9125913-B2. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015) |
| Bcl-2-like 2/Apoptosis regulator Bcl-W in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4677] [GtoPdb: 2846] [UniProtKB: Q92843] | ||||||||
| ChEMBL | Inhibition of Bcl-w (unknown origin) | B | 6.55 | pKi | 285 | nM | Ki | Eur J Med Chem (2019) 177: 63-75 [PMID:31129454] |
| GtoPdb | - | - | 9 | pKi | <1 | nM | Ki | J Med Chem (2007) 50: 641-62 [PMID:17256834] |
| ChEMBL | Binding affinity to Bcl-w | B | 9 | pKi | <1 | nM | Ki | Eur J Med Chem (2012) 57: 112-125 [PMID:23047228] |
| ChEMBL | Binding affinity to Bcl-w (unknown origin) | B | 9 | pKi | <=1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| ChEMBL | Inhibition of Bcl-w (unknown origin) | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2017) 60: 821-838 [PMID:27749061] |
| ChEMBL | Inhibition of BCL-W (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay | B | 9 | pKi | <=1 | nM | Ki | Eur J Med Chem (2019) 167: 76-95 [PMID:30769242] |
| ChEMBL | Binding affinity to Bcl-w (unknown origin) by surface plasmon resonance assay | B | 7.18 | pIC50 | 66 | nM | IC50 | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Displacement of wild type mBimBH3 from human Bcl-w by solution competition assay | B | 7.4 | pIC50 | 40 | nM | IC50 | J Med Chem (2011) 54: 1914-1926 [PMID:21366295] |
| ChEMBL | Inhibition of Bcl-w | B | 9 | pIC50 | <1 | nM | IC50 | Bioorg Med Chem (2012) 20: 4194-4200 [PMID:22739087] |
| Bcl-2-like 1/Apoptosis regulator Bcl-X in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4625] [GtoPdb: 2845] [UniProtKB: Q07817] | ||||||||
| ChEMBL | Binding affinity to Bcl-Xl | B | 9.43 | pKd | 0.37 | nM | Kd | J Med Chem (2011) 54: 1914-1926 [PMID:21366295] |
| ChEMBL | Binding affinity to human GST-tagged Bcl-Xl assessed as dissociation rate by surface plasmon resonance assay | B | 9.89 | pKd | 0.13 | nM | Kd | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y101H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.42 | pKi | 380 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 F97V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.52 | pKi | 300 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.54 | pKi | 290 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Inhibition of Bcl-xL (unknown origin) | B | 6.55 | pKi | 284 | nM | Ki | Eur J Med Chem (2019) 177: 63-75 [PMID:31129454] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.57 | pKi | 270 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 V141A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.72 | pKi | 190 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Inhibition of recombinant His6-tagged Bcl-XL expressed in Escherichia coli BL21 (DE3) and Flu-Bak peptide interaction by fluorescence polarization assay | B | 6.72 | pKi | 188.4 | nM | Ki | J Med Chem (2009) 52: 5937-5949 [PMID:19743858] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 R100E mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 6.8 | pKi | 160 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 7.14 | pKi | 73 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Binding affinity to Bcl-XL (unknown origin) by fluorescence polarization assay | B | 7.19 | pKi | 64 | nM | Ki | Medchemcomm (2016) 7: 778-787 |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 7.24 | pKi | 58 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Binding affinity to Bcl-xl | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2010) 53: 6779-6810 [PMID:20925433] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 7.68 | pKi | 21 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E96G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 8.24 | pKi | 5.8 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E129H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 8.35 | pKi | 4.5 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Wild type Bcl-2-like protein 1 expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 8.47 | pKi | 3.4 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y195F mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 8.82 | pKi | 1.5 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A93V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 8.85 | pKi | 1.4 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Binding affinity to Bcl-xL by competitive fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | Bioorg Med Chem Lett (2012) 22: 39-44 [PMID:22172701] |
| ChEMBL | Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2012) 55: 4664-4682 [PMID:22448988] |
| ChEMBL | Inhibition of human N-terminal His8-tagged Bcl-XL expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BAK binding after 1 to 2 hrs by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2012) 55: 6149-6161 [PMID:22747598] |
| ChEMBL | Binding affinity to Bcl-XL | B | 9 | pKi | <1 | nM | Ki | Eur J Med Chem (2012) 57: 112-125 [PMID:23047228] |
| ChEMBL | Binding affinity to Bcl-XL | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2012) 55: 10735-10741 [PMID:23167494] |
| ChEMBL | Binding affinity to Bcl-xL (unknown origin) | B | 9 | pKi | <=1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| ChEMBL | Inhibition of Bcl-xL (unknown origin) | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2017) 60: 821-838 [PMID:27749061] |
| ChEMBL | Inhibition of Bcl-xL (unknown origin) | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2018) 61: 2636-2651 [PMID:28926247] |
| ChEMBL | Inhibition of BCL-XL (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay | B | 9 | pKi | <=1 | nM | Ki | Eur J Med Chem (2019) 167: 76-95 [PMID:30769242] |
| ChEMBL | Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 G196A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay | B | 9 | pKi | <1 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Displacement of fluorescein-labeled BAK from His-tagged BCL-XL (unknown origin) after 1 hr by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Nat Prod (2014) 77: 1430-1437 [PMID:24901800] |
| ChEMBL | Inhibition of 5-FAM-Bid peptide binding to Bcl-XL (unknown origin) by fluorescence polarization assay | B | 9 | pKi | 1 | nM | Ki | Bioorg Med Chem Lett (2016) 26: 5207-5211 [PMID:27712939] |
| GtoPdb | - | - | 9.3 | pKi | <0.5 | nM | Ki | J Med Chem (2007) 50: 641-62 [PMID:17256834] |
| ChEMBL | Binding affinity to human GST-tagged Bcl-Xl by fluorescence polarization assay | B | 9.3 | pKi | <0.5 | nM | Ki | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Displacement of Bad-derived peptide from Bcl-xL by fluorescence polarization assay | B | 9.3 | pKi | <0.5 | nM | Ki | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Binding affinity to Bcl-xL | B | 9.3 | pKi | <0.5 | nM | Ki | Eur J Med Chem (2012) 51: 286-293 [PMID:22425031] |
| ChEMBL | Inhibition of Bcl-xL | B | 7.19 | pIC50 | 64 | nM | IC50 | J Med Chem (2010) 53: 2577-2588 [PMID:20192224] |
| ChEMBL | Displacement of Bad-derived peptide from Bcl-xL by FPA in presence of 10% human serum | B | 7.22 | pIC50 | <60 | nM | IC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of Bcl-xL (unknown origin) by surface plasmon resonance assay | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2020) 63: 928-943 [PMID:31580668] |
| ChEMBL | Binding affinity to human GST-tagged Bcl-Xl by surface plasmon resonance assay | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay | B | 8.22 | pIC50 | 6 | nM | IC50 | J Med Chem (2012) 55: 4664-4682 [PMID:22448988] |
| ChEMBL | Inhibition of human N-terminal His8-tagged Bcl-XL expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BAK binding after 1 to 2 hrs by fluorescence polarization assay | B | 8.22 | pIC50 | 6 | nM | IC50 | J Med Chem (2012) 55: 6149-6161 [PMID:22747598] |
| ChEMBL | Inhibition of GST-tagged Bcl-xL (unknown origin) measured after 1 hr incubation by fluorescence polarization assay | B | 8.22 | pIC50 | 6 | nM | IC50 | Bioorg Med Chem (2015) 23: 1747-1757 [PMID:25797160] |
| ChEMBL | Displacement of biotinylated Bim-BH3 from GST-tagged Bcl-Xl by AlphaScreen competitive assay | B | 8.52 | pIC50 | 3 | nM | IC50 | J Med Chem (2011) 54: 1914-1926 [PMID:21366295] |
| ChEMBL | Inhibition of Bcl-XL | B | 9 | pIC50 | <1 | nM | IC50 | Bioorg Med Chem (2012) 20: 4194-4200 [PMID:22739087] |
| ChEMBL | Binding affinity to human GST-tagged Bcl-Xl by luminescence proximity assay | B | 9.3 | pIC50 | 0.5 | nM | IC50 | J Med Chem (2013) 56: 5514-5540 [PMID:23767404] |
| ChEMBL | Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin | F | 7.52 | pEC50 | 30 | nM | EC50 | J Med Chem (2007) 50: 641-662 [PMID:17256834] |
| ChEMBL | Inhibition of Bcl-XL | B | 7.52 | pEC50 | 29.99 | nM | EC50 | Eur J Med Chem (2010) 45: 4774-4782 [PMID:20728251] |
| ChEMBL | Inhibition of GST-tagged recombinant Bcl-XL interaction with biotinylated Bim peptide by ELISA based competitive binding assay | B | 8 | pEC50 | <10 | nM | EC50 | Eur J Med Chem (2012) 57: 112-125 [PMID:23047228] |
| Aspartyl/asparaginyl beta-hydroxylase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4680030] [UniProtKB: Q12797] | ||||||||
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.35 | pIC50 | 4470 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.47 | pIC50 | 3380 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis | B | 5.52 | pIC50 | 2990 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| ChEMBL | Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis | B | 5.53 | pIC50 | 2920 | nM | IC50 | Bioorg Med Chem (2020) 28: 115675-115675 [PMID:33069066] |
| Bcl2-antagonist of cell death (BAD) in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3817] [UniProtKB: Q92934] | ||||||||
| ChEMBL | Displacement of fluorescein labeled BAD peptide from Bcl-XL by fluorescence polarization assay | B | 9 | pKi | <1 | nM | Ki | J Med Chem (2008) 51: 6902-6915 [PMID:18841882] |
| ChEMBL | Binding affinity to Bcl-XL assessed as inhibition of Bcl-XL-BAD derived peptide interaction | B | 9.22 | pKi | 0.6 | nM | Ki | Nature (2007) 450: 1001-1009 [PMID:18075579] |
| Bcl-2-like 1 in Human [GtoPdb: 2845] [UniProtKB: Q07817] | ||||||||
| GtoPdb | - | - | 9.3 | pKi | <0.5 | nM | Ki | J Med Chem (2007) 50: 641-62 [PMID:17256834] |
| Bcl-2-like 1/Bcl-2-like protein 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3309112] [GtoPdb: 2845] [UniProtKB: Q64373] | ||||||||
| ChEMBL | Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The inhibition constant (Ki) is the dissociation constant of an enzyme-inhibitor complex or a protein/small molecule complex, wherein the small molecule is inhibiting binding of one protein to another protein or peptide. Where the Ki for a compound is represented as > (greater than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for Bcl-XL) is greater than the limits of detection of the assay used. Where the binding selectivity ratio for a compound is represented as > (greater than) a certain numerical value, it is intended to mean that the selectivity of a particular compound for Bcl-2 over Bcl-XL is at least as great as the number indicated. Where the Ki for a compound is represented as < (less than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for Bcl-2) is lower than the limit of detection of the assay used. Inhibition constants were determined using Wang's equation (Wang Z-X). | B | 10.1 | pKi | 0.08 | nM | Ki | US-9125913-B2. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015) |
| Bcl-2-like protein 10 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5988] [UniProtKB: Q9HD36] | ||||||||
| ChEMBL | Binding affinity to Bcl-b (unknown origin) | B | 9 | pKi | >1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| Bcl-2-related protein A1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6044] [UniProtKB: Q16548] | ||||||||
| ChEMBL | Binding affinity for GST-tagged human BCL2A1 expressed in Escherichia coli BL21 cells | B | 6 | pKd | >1000 | nM | Kd | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| ChEMBL | Binding affinity to Bcl2A1 (unknown origin) | B | 4.7 | pKi | >20000 | nM | Ki | J Med Chem (2017) 60: 821-838 [PMID:27749061] |
| Beta-casein in Bovine (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3313833] [UniProtKB: P02666] | ||||||||
| ChEMBL | Binding affinity to bovine beta-casein A1 | B | 9 | pKi | >1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| MCL1 apoptosis regulator, BCL2 family member/Induced myeloid leukemia cell differentiation protein Mcl-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4361] [GtoPdb: 2847] [UniProtKB: Q07820] | ||||||||
| ChEMBL | Binding affinity to Mcl-1 by competitive fluorescence polarization assay | B | 4 | pKi | >100000 | nM | Ki | Bioorg Med Chem Lett (2012) 22: 39-44 [PMID:22172701] |
| ChEMBL | Displacement of fluorescein-labeled BID from His-tagged MCL-1 (unknown origin) after 1 hr by fluorescence polarization assay | B | 4.68 | pKi | 20800 | nM | Ki | J Nat Prod (2014) 77: 1430-1437 [PMID:24901800] |
| ChEMBL | Binding affinity to Mcl-1 | B | 4.7 | pKi | >20000 | nM | Ki | Eur J Med Chem (2012) 51: 286-293 [PMID:22425031] |
| ChEMBL | Inhibition of 5-FAM-Bid peptide binding to MCL-1 (unknown origin) by fluorescence polarization assay | B | 4.7 | pKi | >20000 | nM | Ki | Bioorg Med Chem Lett (2016) 26: 5207-5211 [PMID:27712939] |
| ChEMBL | Binding affinity to Mcl-1 (unknown origin) | B | 4.7 | pKi | >20000 | nM | Ki | J Med Chem (2017) 60: 821-838 [PMID:27749061] |
| ChEMBL | Binding affinity to induced myeloid leukemia cell differentiation protein 1 (unknown origin) | B | 9 | pKi | >1 | nM | Ki | Bioorg Med Chem (2014) 22: 4474-4489 [PMID:24811300] |
| ChEMBL | Displacement of wild type mBimBH3 from Mcl-1 by solution competition assay | B | 6 | pIC50 | >1000 | nM | IC50 | J Med Chem (2011) 54: 1914-1926 [PMID:21366295] |
| ChEMBL | Binding affinity to N-terminus 8X His-tagged human Mcl1 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay | B | 6 | pIC50 | >1000 | nM | IC50 | J Med Chem (2012) 55: 4664-4682 [PMID:22448988] |
| ChEMBL | Inhibition of human N-terminal His8-tagged Mcl1 expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BID binding after 1 to 2 hrs by fluorescence polarization assay | B | 6 | pIC50 | >1000 | nM | IC50 | J Med Chem (2012) 55: 6149-6161 [PMID:22747598] |
| ChEMBL | Binding affinity to MCL1 (unknown origin) by fluorescence polarization assay | B | 6 | pIC50 | >1000 | nM | IC50 | Medchemcomm (2016) 7: 778-787 |
| MCL1 apoptosis regulator, BCL2 family member/Induced myeloid leukemia cell differentiation protein Mcl-1 homolog in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5768] [GtoPdb: 2847] [UniProtKB: P97287] | ||||||||
| ChEMBL | Binding affinity for GST-tagged mouse MCL1 expressed in Escherichia coli BL21 cells | B | 6 | pKd | >1000 | nM | Kd | Bioorg Med Chem Lett (2011) 21: 4951-4955 [PMID:21807512] |
| MCL1 apoptosis regulator, BCL2 family member/MCL1-BAK1 complex in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3885523] [GtoPdb: 2847] [UniProtKB: Q07820, Q16611] | ||||||||
| ChEMBL | Inhibition of Mcl1-BAK interaction | B | 4.3 | pIC50 | >50000 | nM | IC50 | ACS Med Chem Lett (2012) 3: 579-583 [PMID:24900514] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
